» Articles » PMID: 10644727

Characterization of the Monomeric and Dimeric Forms of Latent and Active Matrix Metalloproteinase-9. Differential Rates for Activation by Stromelysin 1

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2000 Jan 25
PMID 10644727
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Matrix metalloproteinase-9 (MMP-9) is a member of the MMP family that has been associated with degradation of the extracellular matrix in normal and pathological conditions. A unique characteristic of MMP-9 is its ability to exist in a monomeric and a disulfide-bonded dimeric form. However, there exists a paucity of information on the properties of the latent (pro-MMP-9) and active MMP-9 dimer. Here we report the purification to homogeneity of the monomer and dimer forms of pro-MMP-9 and the characterization of their biochemical properties and interactions with tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2. Gel filtration and surface plasmon resonance analyses demonstrated that the pro-MMP-9 monomeric and dimeric forms bind TIMP-1 with similar affinities. In contrast, TIMP-2 binds only to the active forms. After activation, the two enzyme forms exhibited equal catalytic competence in the turnover of a synthetic peptide substrate with comparable kinetic parameters for the onset of inhibition with TIMPs and for dissociation of the inhibited complexes. Kinetic analyses of the activation of monomeric and dimeric pro-MMP-9 by stromelysin 1 revealed K(m) values in the nanomolar range and relative low k(cat) values (1.9 x 10(-3) and 4.1 x 10(-4) s(-1), for the monomer and dimer, respectively) consistent with a faster rate (1 order of magnitude) of activation of the monomeric form by stromelysin 1. This suggests that the rate-limiting event in the activation of pro-MMP-9 may be a requisite slow unfolding of pro-MMP-9 near the site of the hydrolytic cleavage by stromelysin 1.

Citing Articles

Elevated matrix Metalloproteinase-9 associated with reduced cerebellar perineuronal nets in female mice with toxoplasmosis.

Xiao J, Huang J, Yolken R Brain Behav Immun Health. 2024; 36:100728.

PMID: 38323226 PMC: 10844038. DOI: 10.1016/j.bbih.2024.100728.


Metformin Directly Binds to MMP-9 to Improve Plaque Stability.

Chen X, Wang S, Xu W, Zhao M, Zhang Y, Xiao H J Cardiovasc Dev Dis. 2023; 10(2).

PMID: 36826550 PMC: 9962015. DOI: 10.3390/jcdd10020054.


Obeticholic Acid Reduces Kidney Matrix Metalloproteinase Activation Following Partial Hepatic Ischemia/Reperfusion Injury in Rats.

Palladini G, Cagna M, Di Pasqua L, Adorini L, Croce A, Perlini S Pharmaceuticals (Basel). 2022; 15(5).

PMID: 35631351 PMC: 9145209. DOI: 10.3390/ph15050524.


MMP9: A Tough Target for Targeted Therapy for Cancer.

Augoff K, Hryniewicz-Jankowska A, Tabola R, Stach K Cancers (Basel). 2022; 14(7).

PMID: 35406619 PMC: 8998077. DOI: 10.3390/cancers14071847.


C-Peptide Promotes Cell Migration by Controlling Matrix Metallopeptidase-9 Activity Through Direct Regulation of β-Catenin in Human Endometrial Stromal Cells.

Khaliq S, Umair Z, Baek M, Chon S, Yoon M Front Cell Dev Biol. 2022; 10:800181.

PMID: 35127683 PMC: 8814361. DOI: 10.3389/fcell.2022.800181.